title: The Role of Plasma Kallikrein-Kinin Pathway in the Development of Diabetic Retinopathy: Pathophysiology and Therapeutic Approaches.
abstract: Diabetic retinal disease is characterized by a series of retinal microvascular changes and increases in retinal vascular permeability that lead to development of diabetic retinopathy (DR) and diabetic macular edema (DME), respectively. Current treatment strategies for DR and DME are mostly limited to vascular endothelial growth factor (VEGF) inhibitors and laser photocoagulation. These treatment modalities are not universally effective in all patients, and potential side effects persist in a significant portion of patients. The plasma kallikrein-kinin system (KKS) is one of the pathways that has been identified in the vitreous in proliferative DR and DME. Preclinical studies have shown that the activation of intraocular KKS induces retinal vascular permeability, vasodilation, and retinal thickening. Proteomic analysis from vitreous of eyes with DME has shown that KKS and VEGF pathways are potentially independent biologic pathways. Furthermore, proteins associated with DME in the vitreous were significantly more correlated with the KKS pathway compared to VEGF pathway. Preclinical experiments on diabetic animals showed that inhibition of KKS components was found to be an effective approach to decrease retinal vascular permeability. An initial phase I human trial of a novel plasma kallikrein inhibitor for the treatment of DME is currently ongoing to test the safety of this approach and serves as an initial step in the translation of basic science discovery into an innovative clinical intervention.
authors.affiliation: a Beetham Eye Institute, Joslin Diabetes Center , Boston , Massachusetts , USA , and.|b Department of Ophthalmology , Harvard Medical School , Boston , Massachusetts , USA.
authors.forename: Marwan
authors.initials: M
authors.lastname: Abdulaal
authors.affiliation: a Beetham Eye Institute, Joslin Diabetes Center , Boston , Massachusetts , USA , and.|b Department of Ophthalmology , Harvard Medical School , Boston , Massachusetts , USA.
authors.forename: Nour Maya N
authors.initials: NM
authors.lastname: Haddad
authors.affiliation: a Beetham Eye Institute, Joslin Diabetes Center , Boston , Massachusetts , USA , and.|b Department of Ophthalmology , Harvard Medical School , Boston , Massachusetts , USA.
authors.forename: Jennifer K
authors.initials: JK
authors.lastname: Sun
authors.affiliation: a Beetham Eye Institute, Joslin Diabetes Center , Boston , Massachusetts , USA , and.|b Department of Ophthalmology , Harvard Medical School , Boston , Massachusetts , USA.
authors.forename: Paolo S
authors.initials: PS
authors.lastname: Silva
mesh_terms: D000818:Animals; D002199:Capillary Permeability; D003930:Diabetic Retinopathy / Q000503:physiopathology* / Q000628:therapy; D006801:Humans; D016234:Kallikrein-Kinin System / Q000502:physiology*; D008269:Macular Edema / Q000503:physiopathology* / Q000628:therapy; D020842:Plasma Kallikrein / Q000502:physiology; D012171:Retinal Vessels / Q000502:physiology; D042461:Vascular Endothelial Growth Factor A / Q000502:physiology
chemical_list: C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D020842:Plasma Kallikrein
keywords: Diabetic macular edema; diabetic retinopathy; plasma kallikrein-kinin